Blockchain Registration Transaction Record

VolitionRx Seeks French Reimbursement for Lung Cancer Blood Test

VolitionRx prepares reimbursement submission for its Nu.Q® Cancer blood test in France, supported by Hospices Civils de Lyon, aiming for routine use in lung cancer management.

This development matters because it represents a critical step toward making a potentially life-saving diagnostic tool more accessible. Lung cancer is a leading cause of cancer death worldwide, and early, accurate information about disease progression is crucial for treatment planning. If Volition's Nu.Q® Cancer test becomes a reimbursed part of routine care in France, it could help doctors better stratify patients—identifying those with more aggressive disease who need intensive therapy and those who might avoid overtreatment. This precision can improve survival rates and quality of life. Furthermore, success in France, a major European healthcare market, often paves the way for adoption in other countries, accelerating global access to innovative diagnostics. For patients and families facing a lung cancer diagnosis, tools that offer clearer prognostic insights can reduce uncertainty and guide more personalized, effective care.